Wells Fargo maintains Universal Health Services at Equal-Weight, raises price target to $170 from $166

Wells Fargo kept its Equal-Weight rating on Universal Health Services but increased its price target to $170 from $166, suggesting a 3.4% downside from the last close at $176.05.

Original reporting
Published Nov 2, 2026, 1:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 2:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wells Fargo maintains Universal Health Services at Equal-Weight, raises price target to $170 from $166 — source image
Decision brief

The 30-second read

$UHSNeutralLow
01

Why it matters

The analyst's modest target increase suggests a slight positive view but does not indicate a major catalyst.

02

Market read

A small analyst target raise with limited immediate trading impact.

03

What to watch

Potential upcoming earnings or regulatory developments could outweigh the small target adjustment.

Relevance 5/10Novelty 4/10Timing: today

Background

Wells Fargo maintains an Equal‑Weight rating on UHS and adjusts its price target upward by 2.4%.

Company-level read

Ticker impact

$UHSNeutralMedium confidence
Context

Wells Fargo raised its price target on Universal Health Services to $170 from $166.

Expected impact

likely slight pressure as the market prices in the modest target increase but still sees upside limited

Evidence & confidence

Target raise is small (2.4%) and does not change the overall valuation; traders may hold or trim positions.

Market effects

Minimal impact on the healthcare services sector; other providers unlikely to be affected.

No regional effect; the news is company‑specific.

Limited relevance beyond UHS investors.

Counterpoint

The target raise is modest and may not justify buying; the stock could still be overvalued at current levels.

Key entities

  • Wells Fargo

    Equity research firm providing the rating and target.

  • Universal Health Services

    Provider of hospital and behavioral health services.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$CNCMed

Health insurers, hospitals rally after sweeping midterm win for Democrats

Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.

$UHSHighAI 8/10

Softer surgery volumes, hospital woes dampened UHS’ Q3 earnings

Universal Health Services (UHS) lowered its 2026 earnings expectations due to declining surgeries and struggles at some hospitals. Q3 net income fell 17% to $308M, while revenues rose 5% to $4.7B. Challenges include lower surgery volumes, delays in new hospital profitability, and rising uninsured patients. UHS expects to be at the lower end of its guidance range for 2024.

$UHSMed

Guggenheim cuts Universal Health Services stock price target to $201 on weak Q3

Guggenheim reduced its price target for Universal Health Services (UHS) to $201 from $209, citing weak Q3 2026 EBITDA and macro pressures. UHS stock is down 8.5% in a week. The company lowered its 2026 EBITDA guidance but sees potential upside from expansions. UHS reported Q3 EPS of $5.22 and revenue of $4.73B, slightly beating estimates. Raymond James kept a Market Perform rating, noting softer profit trends and a cautious 2027 outlook.